BioCryst Pharmaceuticals Inc
NASDAQ:BCRX

Watchlist Manager
BioCryst Pharmaceuticals Inc Logo
BioCryst Pharmaceuticals Inc
NASDAQ:BCRX
Watchlist
Price: 7.6 USD 1.47% Market Closed
Market Cap: 1.6B USD
Have any thoughts about
BioCryst Pharmaceuticals Inc?
Write Note

Gross Margin
BioCryst Pharmaceuticals Inc

98.1%
Current
98%
Average
63.9%
Industry

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
98.1%
=
Gross Profit
404.6m
/
Revenue
412.6m

Gross Margin Across Competitors

Country US
Market Cap 1.6B USD
Gross Margin
98%
Country FR
Market Cap 6T USD
Gross Margin
0%
Country US
Market Cap 312.7B USD
Gross Margin
67%
Country US
Market Cap 158.3B USD
Gross Margin
60%
Country US
Market Cap 115.9B USD
Gross Margin
86%
Country US
Market Cap 112.4B USD
Gross Margin
78%
Country US
Market Cap 94.1B EUR
Gross Margin
76%
Country AU
Market Cap 133.6B AUD
Gross Margin
52%
Country US
Market Cap 82.6B USD
Gross Margin
87%
Country US
Market Cap 39.3B EUR
Gross Margin
75%
Country NL
Market Cap 34.5B EUR
Gross Margin
89%
No Stocks Found

BioCryst Pharmaceuticals Inc
Glance View

Market Cap
1.6B USD
Industry
Biotechnology

BioCryst Pharmaceuticals, Inc. is a commercial-stage biotechnology company that discovers novel, oral, and small-molecule medicines. The company is headquartered in Durham, North Carolina and currently employs 358 full-time employees. ORLADEYO (berotralstat) is an oral, once-daily therapy that is approved in the United States, the European Union, Japan, and the United Kingdom for the prevention of hereditary angioedema attacks in adults and pediatric patients 12 years and older. The firm has several ongoing development programs, including BCX9930, an oral Factor D inhibitor for the treatment of complement-mediated diseases; BCX9250, an activin receptor-like kinase-2 inhibitor for the treatment of fibrodysplasia ossificans progressiva, and galidesivir, an antiviral drug for Marburg virus disease and Yellow Fever. RAPIVAB (peramivir injection) is a viral neuraminidase inhibitor for the treatment of influenza, has received regulatory approval in the United States, Canada, Australia, Japan, Taiwan and Korea.

BCRX Intrinsic Value
11.3 USD
Undervaluation 33%
Intrinsic Value
Price

See Also

Discover More
What is Gross Margin?

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
98.1%
=
Gross Profit
404.6m
/
Revenue
412.6m
What is the Gross Margin of BioCryst Pharmaceuticals Inc?

Based on BioCryst Pharmaceuticals Inc's most recent financial statements, the company has Gross Margin of 98.1%.